PeterP.SteinMD

Diabetes, Lipid Metabolism

Physician

Dr. Stein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
125 Paterson St
Clinical Academic Building Suite 5100a
New Brunswick, NJ 08901
Phone+1 732-235-7219

Fax+1 732-212-0713

Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1985 - 1988
Yale-New Haven Medical CenterResidency, Internal Medicine, 1981 - 1984
Perelman School of Medicine at the University of PennsylvaniaClass of 1981

PubMed

120 citations
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
Viswanathan Mohan, Wenying Yang, Ho-Young Son, Lei Xu, Liliane Noble
Diabetes Research and Clinical Practice. 2009-01-01
1756 citations
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel
The New England Journal of Medicine. 2015-07-15
69 citations
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
L. Xu, C. Dalla Man, B. Charbonnel, G. Meninger, Melanie J. Davies
Diabetes, Obesity & Metabolism. 2008-12-01

Hello Semglee: New Low-Priced ‘Interchangeable’ Insulin Is First of Its KindAugust 1st, 2021
Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-on Biologic Insulin GlargineAugust 5th, 2016
Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to LantusJune 13th, 2016
Join now to see all